Clinical Trials Directory

Trials / Completed

CompletedNCT02003924

Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer

PROSPER: A MULTINATIONAL, PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE IN PATIENTS WITH NONMETASTATIC CASTRATION-RESISTANT PROSTATE CANCER

Status
Completed
Phase
Phase 3
Study type
Interventional
Enrollment
1,401 (actual)
Sponsor
Pfizer · Industry
Sex
Male
Age
18 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to assess the safety and efficacy of enzalutamide in patients with non metastatic prostate cancer.

Conditions

Interventions

TypeNameDescription
DRUGEnzalutamide160 mg by mouth once daily
DRUGPlaceboSugar pill to mimic enzalutamide

Timeline

Start date
2013-10-31
Primary completion
2017-06-28
Completion
2025-11-28
First posted
2013-12-06
Last updated
2026-01-27
Results posted
2018-07-12

Locations

397 sites across 32 countries: United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Denmark, Finland, France, Germany, Greece, Hong Kong, Italy, Malaysia, Netherlands, New Zealand, Poland, Russia, Serbia, Singapore, Slovakia, South Korea, Spain, Sweden, Taiwan, Thailand, Turkey (Türkiye), Ukraine, United Kingdom

Source: ClinicalTrials.gov record NCT02003924. Inclusion in this directory is not an endorsement.